Table 3.

DAPSA components in women (n=219) and men (n=221) with PsA by treatment target state

Target status	DAPSA≤14 (at target)			DAPSA>14 (not at target)
DAPSA variables Mean (SD)	Women (n=103)	Men (n=148)	p-value	Women (n=116)	Men (n=73)	p-value
TJC68	0.8 (1.2)	0.5 (1.0)	0.028	9.6 (11.3)	10.3 (14.6)	0.745
SJC66	0.5 (1.1)	0.3 (0.8)	0.193	3.6 (7.5)	5.4 (11.2)	0.214
Pain VAS	2.7 (1.9)	2.1 (1.7)	0.018	6.6 (2.0)	6.0 (2.3)	0.112
Patient global VAS	3.0 (2.0)	2.2 (1.9)	0.003	6.4 (2.0)	6.0 (2.3)	0.167
CRP (mg/L)	0.6 (1.3)	0.6 (1.3)	0.665	3.1 (8.9)	2.3 (5.7)	0.452

Bold font designates significant p-values. Abbreviations: SD standard deviation, TJC68 tender joint count range 0–68, SJC66 swollen joint count range 0–66, LEI Leeds enthesitis index range 0–6, BSA body surface area range 0–100%, VAS visual analog scale range 0–10, HAQ-DI Health Assessment Questionnaire Disability index range 0–3, PsAID Psoriatic Arthritis Impact of Disease range 0–10, CRP C-Reactive Protein.

Missing values (9 women and 9 men had missing values for DAPSA, missing for (women, men): TJC68 (0,2), SJC66 (0,2), Pain VAS (1,1), Patient global VAS (1,2), CRP (7,8)